|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Merck & Co., Inc., a global research-based pharmaceutical and vaccine manufacturer. |
|---|---|
| Transferring Party | NovaCardia, Inc., a pharmaceutical developer of an experimental treatment for acute congestive heart failure. |
| Sector | Biopharmaceuticals |
| Date | September 11, 2007 |
| Analysis NovaCardia's lead product candidate, being studied in Phase 3 clinical trials, is believed to protect kidneys from effects of diuretics often given to patients as part of their treatment for congestive heart failure. A niche acquisition addressing an unmet medical need in an area important for Merck. Deal value -- $366.4m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |